Epidemiology, morbidity and mortality in Behçet's disease: a cohort study using The Health Improvement Network (THIN).


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
01 10 2020
Historique:
received: 18 07 2019
revised: 16 12 2019
pubmed: 11 2 2020
medline: 26 1 2021
entrez: 11 2 2020
Statut: ppublish

Résumé

The epidemiology of Behçet's disease (BD) has not been well characterized in the UK. Evidence on the risk of cardiovascular disease, thromboembolic disease and mortality in patients with BD compared with the general population is scarce. We used a large UK primary care database to investigate the epidemiology of BD. A retrospective matched cohort study was used to assess the following outcomes: risk of cardiovascular, thromboembolic disease and mortality. Controls were selected at a 1:4 ratio (age and gender matched). Cox proportional hazard models were used to derive adjusted hazard ratios (aHR). The prevalence of BD was 14.61 (95% CI 13.35-15.88) per 100 000 population in 2017. A total of 1281 patients with BD were compared with 5124 age- and gender-matched controls. There was significantly increased risk of ischaemic heart disease [aHR 3.09 (1.28-7.44)], venous thrombosis [aHR 4.80 (2.42-9.54)] and mortality [aHR 1.40 (1.07-1.84)] in patients with BD compared with corresponding controls. Patients with BD were at higher risk of pulmonary embolism compared with corresponding controls at baseline [adjusted odds ratio 4.64 (2.66-8.09), P < 0.0001]. The majority of patients with pulmonary embolism and a diagnosis of BD had pulmonary embolism preceding the diagnosis of BD, not after (87.5%; n = 28/32). BD has a higher prevalence than previously thought. Physicians should be aware of the increased risk of developing ischaemic heart disease, stroke/transient ischaemic attack and deep venous thrombosis in patients with BD at an earlier age compared with the general population. Risk of embolism in patients with BD might vary across the disease course.

Identifiants

pubmed: 32040196
pii: 5732862
doi: 10.1093/rheumatology/keaa010
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2785-2795

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Tom Thomas (T)

Translational Gastroenterology Unit, University of Oxford, OxfordUK.
Kennedy Institute of Rheumatology, University of Oxford, OxfordUK.
Wellcome Centre for Human Genetics, University of Oxford, OxfordUK.
Institute of Applied Health Research, University of Birmingham, BirminghamUK.

Joht Singh Chandan (JS)

Institute of Applied Health Research, University of Birmingham, BirminghamUK.
Warwick Medical School, University of Warwick, WarwickUK.

Anuradhaa Subramanian (A)

Institute of Applied Health Research, University of Birmingham, BirminghamUK.

Krishna Gokhale (K)

Institute of Applied Health Research, University of Birmingham, BirminghamUK.

George Gkoutos (G)

Institute of Applied Health Research, University of Birmingham, BirminghamUK.

Lorraine Harper (L)

Institute of Clinical Sciences, Centre for Translational Inflammation Research, University of Birmingham, BirminghamUK.

Christopher Buckley (C)

Kennedy Institute of Rheumatology, University of Oxford, OxfordUK.
Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.

Priyanka Chandratre (P)

Birmingham National Centre of Excellence for Behcet's Disease, Sandwell and West Hospitals Birmingham, Birmingham, UK.

Karim Raza (K)

Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.

Deva Situnayake (D)

Birmingham National Centre of Excellence for Behcet's Disease, Sandwell and West Hospitals Birmingham, Birmingham, UK.

Krishnarajah Nirantharakumar (K)

Institute of Applied Health Research, University of Birmingham, BirminghamUK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH